AngioDynamics (NASDAQ:ANGO) Stock Price Crosses Above Two Hundred Day Moving Average – What’s Next?

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $11.95 and traded as high as $16.05. AngioDynamics shares last traded at $15.82, with a volume of 335,653 shares trading hands.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Canaccord Genuity Group increased their price objective on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. HC Wainwright raised their price target on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Finally, Zacks Research downgraded AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, AngioDynamics currently has an average rating of “Hold” and a consensus target price of $19.50.

AngioDynamics Trading Down 1.6%

The stock’s 50-day moving average is $13.81 and its 200-day moving average is $11.99. The stock has a market cap of $653.43 million, a price-to-earnings ratio of -18.17 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. The business had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, equities analysts predict that AngioDynamics, Inc. will post -0.25 earnings per share for the current fiscal year.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 23,370 shares of the business’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the transaction, the senior vice president owned 64,745 shares in the company, valued at $953,046.40. The trade was a 26.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 6.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ANGO. BlackRock Inc. bought a new stake in AngioDynamics in the second quarter valued at about $49,480,000. Millennium Management LLC grew its position in AngioDynamics by 28.1% in the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock worth $20,030,000 after purchasing an additional 393,682 shares during the last quarter. Kotler Kevin bought a new stake in shares of AngioDynamics during the fourth quarter valued at approximately $21,997,000. Armistice Capital LLC boosted its position in AngioDynamics by 3.9% during the 4th quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock worth $21,828,000 after acquiring an additional 64,000 shares during the period. Finally, Weber Capital Management LLC ADV acquired a new stake in AngioDynamics in the fourth quarter worth about $17,978,000. 89.43% of the stock is owned by institutional investors and hedge funds.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.